FDA pilot program aims to speed up early-stage clinical trials
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Experimental Drug Yields Dramatic Weight Loss
An experimental shot helped participants in a large trial lose far more weight than obesity drugs already on…
F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
The Food and Drug Administration said on Friday that it would permit some patients with deadly pancreatic cancer…
Multicentre gene therapy for OTOF-related deafness followed up to 2.5 years
Yasunaga, S. et al. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form…
WWE Superstars visit pediatric research participants at NIH Clinical Center and The Children’s Inn
Friday, December 12, 2025 Pediatric research participants at the National Institutes of Health (NIH) Clinical Center and The…
Tip Sheet: How patient advocacy shapes research and care, how HIV/AIDS research benefits other diseases — and invasive lobular breast cancer awareness
SEATTLE — Nov. 4, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient…
Tip Sheet: How patient advocacy shapes research and care, how HIV/AIDS research benefits other diseases — and invasive lobular breast cancer awareness
SEATTLE — Nov. 4, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient…
CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission
When JC Cox was diagnosed with a type of non-Hodgkin lymphoma called follicular lymphoma in 2006, the now-retired…
New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…